NO20054134D0 - Renseprosess - Google Patents

Renseprosess

Info

Publication number
NO20054134D0
NO20054134D0 NO20054134A NO20054134A NO20054134D0 NO 20054134 D0 NO20054134 D0 NO 20054134D0 NO 20054134 A NO20054134 A NO 20054134A NO 20054134 A NO20054134 A NO 20054134A NO 20054134 D0 NO20054134 D0 NO 20054134D0
Authority
NO
Norway
Prior art keywords
cleaning process
cleaning
Prior art date
Application number
NO20054134A
Other languages
English (en)
Other versions
NO336672B1 (no
NO20054134L (no
Inventor
Emmanuel Mertens
Ralph Biemans
Karine Goraj
Annick Vandercammen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305792A external-priority patent/GB0305792D0/en
Priority claimed from GB0305791A external-priority patent/GB0305791D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20054134D0 publication Critical patent/NO20054134D0/no
Publication of NO20054134L publication Critical patent/NO20054134L/no
Publication of NO336672B1 publication Critical patent/NO336672B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20054134A 2003-03-13 2005-09-06 Prosess for rensing av et bakterielt cytolysin NO336672B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305792A GB0305792D0 (en) 2003-03-13 2003-03-13 Purification Process
GB0305791A GB0305791D0 (en) 2003-03-13 2003-03-13 Detoxification process
PCT/EP2004/002641 WO2004081515A2 (en) 2003-03-13 2004-03-11 Purification process for bacterial cytolysin

Publications (3)

Publication Number Publication Date
NO20054134D0 true NO20054134D0 (no) 2005-09-06
NO20054134L NO20054134L (no) 2005-10-04
NO336672B1 NO336672B1 (no) 2015-10-19

Family

ID=32992596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054134A NO336672B1 (no) 2003-03-13 2005-09-06 Prosess for rensing av et bakterielt cytolysin

Country Status (23)

Country Link
US (3) US8084235B2 (no)
EP (1) EP1601689B1 (no)
JP (2) JP4597123B2 (no)
KR (1) KR101052996B1 (no)
CN (1) CN101818185B (no)
AU (2) AU2004219910B2 (no)
BR (1) BRPI0408094A (no)
CA (2) CA2518669C (no)
CY (1) CY1107134T1 (no)
DE (1) DE602004010376T2 (no)
DK (1) DK1601689T3 (no)
EG (1) EG24449A (no)
ES (1) ES2295836T3 (no)
HK (1) HK1086013A1 (no)
IL (1) IL210984A0 (no)
IS (1) IS2587B (no)
MA (1) MA27666A1 (no)
MX (1) MXPA05009579A (no)
NO (1) NO336672B1 (no)
NZ (1) NZ541969A (no)
PT (1) PT1601689E (no)
RU (1) RU2340627C2 (no)
WO (1) WO2004081515A2 (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518669C (en) 2003-03-13 2014-07-29 Glaxosmithkline Biologicals S.A. Purification process
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
KR101532778B1 (ko) 2005-03-23 2015-06-30 오클루스 이노바티브 사이언시즈 인코포레이티드 산화 환원 전위 수용액을 사용한 2도 및 3도 화상의 치료방법
KR20130122810A (ko) * 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
EP3470080A1 (en) 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20070196434A1 (en) 2006-01-20 2007-08-23 Oculus Innovative Sciences, Inc. Methods of preventing or treating sinusitis with oxidative reductive potential water solution
NZ575272A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Inactivated poliovirus type 1, diptheria toxoid, tetanus toxoid and killed whole-cell Bordetella pertussis vaccine
LT2144924T (lt) * 2007-04-16 2016-10-10 Minervax Aps Sulieto baltymo vakcina
EP2142211A1 (en) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccine
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
KR20110050531A (ko) * 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
US10342825B2 (en) 2009-06-15 2019-07-09 Sonoma Pharmaceuticals, Inc. Solution containing hypochlorous acid and methods of using same
HUE037416T2 (hu) 2009-09-03 2018-08-28 Pfizer Vaccines Llc PCSK9 vakcina
CN102971009A (zh) 2009-10-30 2013-03-13 诺华有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP5917682B2 (ja) * 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
SG194733A1 (en) * 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
US9938326B2 (en) 2012-09-19 2018-04-10 Osaka University Pneumococcal vaccine containing pneumococcal surface protein A
WO2014084672A1 (ko) 2012-11-30 2014-06-05 (주)바이오니아 전자동 무세포 단백질 제조장비 및 이를 이용한 단백질의 제조방법
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096786B1 (en) 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
KR102099741B1 (ko) 2014-01-21 2020-04-10 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
US9218427B1 (en) * 2015-01-21 2015-12-22 Maana, Inc. Dynamic semantic models having multiple indices
CN108025053A (zh) * 2015-04-16 2018-05-11 创赏有限公司 百日咳杆菌免疫原性的疫苗组合物
RU2721128C2 (ru) 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
MX2019001342A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de proteina-polisacarido de neumococo multivalente.
AU2017306708B2 (en) 2016-08-05 2021-08-26 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US20190360013A1 (en) * 2016-12-02 2019-11-28 President And Fellows Of Harvard College Processive Template Independent DNA Polymerase Variants
JP7186166B2 (ja) 2016-12-30 2022-12-08 バックスサイト・インコーポレイテッド 非天然アミノ酸とのポリペプチド抗原接合体
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (ja) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
EP3678654B1 (en) 2017-09-07 2024-06-26 Merck Sharp & Dohme LLC Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
KR20230130153A (ko) 2017-12-06 2023-09-11 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2020007939A (es) 2018-02-05 2020-09-03 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente nuemococica.
BR112020021296A2 (pt) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
US20220296695A1 (en) 2018-12-19 2022-09-22 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
AU2021223184A1 (en) 2020-02-23 2022-08-18 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
JP2024522395A (ja) 2021-05-28 2024-06-19 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
HUT58804A (en) * 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
DE4133707A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
GB9216351D0 (en) * 1992-07-31 1992-09-16 Wellcome Found Vaccine production
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
JPH10512758A (ja) * 1995-01-27 1998-12-08 ジェネンコア インターナショナル インコーポレーテッド 界面活性剤に基づく抽出法
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5667786A (en) * 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
AR022963A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
JP4132694B2 (ja) * 2000-03-10 2008-08-13 独立行政法人科学技術振興機構 受容体認識部位が保存された生理活性物質の誘導体及びその使用方法
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2518669C (en) 2003-03-13 2014-07-29 Glaxosmithkline Biologicals S.A. Purification process
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process

Also Published As

Publication number Publication date
JP5683866B2 (ja) 2015-03-11
CN101818185B (zh) 2016-05-25
JP4597123B2 (ja) 2010-12-15
RU2005125832A (ru) 2006-04-27
NO336672B1 (no) 2015-10-19
CA2812817C (en) 2016-12-20
WO2004081515A2 (en) 2004-09-23
US20070026010A1 (en) 2007-02-01
EP1601689A2 (en) 2005-12-07
ES2295836T3 (es) 2008-04-16
BRPI0408094A (pt) 2006-02-14
US8815254B2 (en) 2014-08-26
HK1086013A1 (en) 2006-09-08
CA2518669C (en) 2014-07-29
NZ541969A (en) 2008-01-31
NO20054134L (no) 2005-10-04
IL210984A0 (en) 2011-04-28
DE602004010376T2 (de) 2008-10-23
MA27666A1 (fr) 2005-12-01
CA2518669A1 (en) 2004-09-23
US8084235B2 (en) 2011-12-27
MXPA05009579A (es) 2005-11-17
IS2587B (is) 2010-02-15
IS7993A (is) 2005-08-18
DK1601689T3 (da) 2008-03-25
WO2004081515A3 (en) 2004-11-11
EG24449A (en) 2009-07-13
PT1601689E (pt) 2008-01-04
AU2004219910B2 (en) 2010-06-17
EP1601689B1 (en) 2007-11-28
KR20050111357A (ko) 2005-11-24
JP2006520205A (ja) 2006-09-07
AU2010212257A1 (en) 2010-09-02
US8309327B2 (en) 2012-11-13
US20110311577A1 (en) 2011-12-22
RU2340627C2 (ru) 2008-12-10
AU2004219910A1 (en) 2004-09-23
CA2812817A1 (en) 2004-09-23
JP2010259448A (ja) 2010-11-18
CN101818185A (zh) 2010-09-01
DE602004010376D1 (de) 2008-01-10
KR101052996B1 (ko) 2011-07-29
US20140010843A1 (en) 2014-01-09
AU2010212257B2 (en) 2012-08-30
CY1107134T1 (el) 2012-10-24

Similar Documents

Publication Publication Date Title
NO20054134D0 (no) Renseprosess
DE602004017053D1 (de) Wasserzersetzbare reinigungstücher
DK1524928T3 (da) Tandbørster
DE602004019373D1 (de) Bilderzeugungsverfahren
NO20055459D0 (no) Prosesser
ATE333815T1 (de) Zahnbürste
DE112004000372D2 (de) Destillationsverfahren
DK1374670T3 (da) Rengöringsindretning
DE602004027574D1 (de) Reinigungstupfer
DE602004029704D1 (de) Reinigungsmittel
NO20022644D0 (no) Renseprosess
DE602004030703D1 (de) Reinigungsvorrichtung
DE602004013124D1 (de) Schleifverfahren
DE602004030875D1 (de) Duschkopf
ATE359703T1 (de) Aquakulturverfahren
DE602004024308D1 (de) Immunchromatographisches verfahren
ITMO20030335A1 (it) Apparato per pulizie.
FR2863874B1 (fr) Composition demaquillante
DE602004024640D1 (de) Reinigung von titantetrachlorid
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
ATE377067T1 (de) Aufbrausendes reinigungsmittel
SE0301477D0 (sv) New process
SE0301478D0 (sv) New process
SE0302380D0 (sv) New process
ITMI20030249V0 (it) Macchina di pulizia

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees